- ICH GCP
- Register voor klinische proeven in de VS.
- Klinische proef NCT07641764
3D Printed vs Ready-to-Wear Insoles for Diabetic Neuropathy (3DP-DPN)
14 juni 2026 bijgewerkt door: Anbreena Rasool, University of Faisalabad
Comparative Effect of 3D Printed Customized Insoles and Ready to Wear Insoles on Plantar Pressure Changes in Patients With Diabetic Neuropathy
Diabetic neuropathy is a condition caused by chronic high blood glucose levels that damage nerves over time, frequently causing abnormal plantar pressure and increasing the risk of foot ulcers and impaired mobility.
Insoles are widely used to redistribute pressure and improve comfort.
This study compares the effect of 3D printed customized insoles versus ready-to-wear insoles on plantar pressure changes in patients with diabetic neuropathy.
The study is a randomized controlled trial with 22 participants randomly allocated to two groups: one receiving 3D printed customized insoles and the other receiving ready-to-wear insoles.
Plantar pressure is measured using piezoresistive sensors and an Arduino Nano Unit.
Secondary outcomes include foot health status (FSHQ questionnaire), satisfaction with assistive technology (QUEST 2.0), and neuropathy severity (NSS and NDS questionnaires).
Assessments occur at baseline, 4 weeks, and 8 weeks.
Studie Overzicht
Toestand
Actief, niet wervend
Interventie / Behandeling
Gedetailleerde beschrijving
This is a single-blind, parallel-group randomized controlled trial conducted at DHQ-1 and DHQ-2 hospitals in Okara, Pakistan.
Participants are adults aged 35-65 years with diagnosed diabetic neuropathy who can walk independently without aids.
Exclusion criteria include foot ulcers, external wounds, recent surgery, major limb amputation, foot drop, peripheral vascular disease, neuromuscular diseases, and Charcot arthropathy.
A consecutive sampling technique is used to recruit 22 participants.
Randomization is performed using a computer-generated sequence.
Participants are blinded to their group allocation.
Group A receives 3D printed customized insoles tailored to individual foot morphology using 3D scanning and printing technology.
These insoles provide arch support and gait alignment.
Group B receives ready-to-wear insoles providing general cushioning and basic support.
Both groups follow an 8-week intervention protocol: participants wear insoles for a minimum of 6 hours per day, 5 days per week, and perform level walking on a 28-meter pathway at self-selected speed.
The protocol is divided into phases: weeks 1-2 for acclimatization and footwear assessment using Semmes-Weinstein 10g monofilament; weeks 3-4 for pressure adaptation and skin monitoring; weeks 5-6 for enhanced foot function and balance improvement; weeks 7-8 for final assessment.
Primary outcome: plantar pressure measured via piezoresistive sensors and Arduino Nano Unit.
Secondary outcomes: Foot Health Status Questionnaire (FSHQ), Quebec User Evaluation of Satisfaction with Assistive Technology (QUEST 2.0), Neuropathy Symptom Score (NSS), and Neuropathy Deficit Score (NDS).
Data are collected at baseline, week 4, and week 8. Statistical analysis uses SPSS version 22.
Studietype
Ingrijpend
Inschrijving (Geschat)
22
Fase
- Niet toepasbaar
Contacten en locaties
In dit gedeelte vindt u de contactgegevens van degenen die het onderzoek uitvoeren en informatie over waar dit onderzoek wordt uitgevoerd.
Studie Locaties
-
-
Punjab Province
-
Faisalābad, Punjab Province, Pakistan, 3800
- The University of Faisalabad
-
-
Deelname Criteria
Onderzoekers zoeken naar mensen die aan een bepaalde beschrijving voldoen, de zogenaamde geschiktheidscriteria. Enkele voorbeelden van deze criteria zijn iemands algemene gezondheidstoestand of eerdere behandelingen.
Geschiktheidscriteria
Leeftijden die in aanmerking komen voor studie
- Volwassen
- Oudere volwassene
Accepteert gezonde vrijwilligers
Nee
Beschrijving
Inclusion Criteria:
- Age 35 to 65 years
- Diagnosed with diabetes mellitus
- Clinical diagnosis of diabetic peripheral neuropathy
- Ability to walk independently without walking aids
- Normal cognitive function
- Corrected or uncorrected vision sufficient for safe ambulation
- Willingness to provide written informed consent
Exclusion Criteria:
- Presence of active foot ulcer
- External wound on lower extremity
- History of lower limb surgery within past 6 months
- Major lower limb amputation
- Foot drop
- Peripheral vascular disease
- Neuromuscular diseases (e.g., stroke, Parkinson's disease, multiple sclerosis)
- Charcot arthropathy
- Inability to comply with study protocol
Studie plan
Dit gedeelte bevat details van het studieplan, inclusief hoe de studie is opgezet en wat de studie meet.
Hoe is de studie opgezet?
Ontwerpdetails
- Primair doel: Behandeling
- Toewijzing: Gerandomiseerd
- Interventioneel model: Parallelle opdracht
- Masker: Enkel
Wapens en interventies
Deelnemersgroep / Arm |
Interventie / Behandeling |
|---|---|
|
Experimenteel: Group A: 3D Printed Customized Insoles
Participants in this group receive 3D printed customized insoles tailored to individual foot morphology.
Insoles are designed to provide arch support and gait alignment.
Participants wear insoles for minimum 6 hours/day, 5 days/week for 8 weeks, following a phased protocol of acclimatization, pressure adaptation, and function improvement.
|
3D printed customized insoles are fabricated using 3D scanning of the participant's foot to capture individual morphology.
The insoles are printed using thermoplastic polyurethane (TPU) or similar 3D printing filament.
The intervention involves daily wear of insoles for minimum 6 hours per day, 5 days per week, for 8 weeks.
Participants perform level walking on a 28-meter pathway at self-selected speed.
Weekly assessments monitor adherence, skin condition, and comfort.
Patient education on foot care and insole use is provided.
Ready-to-wear insoles are prefabricated insoles providing general cushioning and shock absorption.
These insoles are not customized to individual foot morphology.
The intervention involves daily wear of insoles for minimum 6 hours per day, 5 days per week, for 8 weeks.
Participants perform level walking on a 28-meter pathway at self-selected speed.
Weekly assessments monitor adherence, skin condition, and comfort.
Patient education on foot care and insole use is provided.
|
|
Actieve vergelijker: Group B: Ready-to-Wear Insoles
Participants in this group receive prefabricated ready-to-wear insoles providing general cushioning and basic support.
Participants wear insoles for minimum 6 hours/day, 5 days/week for 8 weeks, following the same phased protocol as the experimental group.
|
Ready-to-wear insoles are prefabricated insoles providing general cushioning and shock absorption.
These insoles are not customized to individual foot morphology.
The intervention involves daily wear of insoles for minimum 6 hours per day, 5 days per week, for 8 weeks.
Participants perform level walking on a 28-meter pathway at self-selected speed.
Weekly assessments monitor adherence, skin condition, and comfort.
Patient education on foot care and insole use is provided.
|
Wat meet het onderzoek?
Primaire uitkomstmaten
Uitkomstmaat |
Maatregel Beschrijving |
Tijdsspanne |
|---|---|---|
|
Change in Plantar Pressure Distribution
Tijdsspanne: Baseline (Week 0), Mid-intervention (Week 4), Post-intervention (Week 8)
|
Plantar pressure is measured using piezoresistive sensors connected to an Arduino Nano Unit.
Participants walk barefoot across the sensor platform.
The sensor records pressure distribution across the plantar surface in kilopascals (kPa).
Higher pressure values indicate greater plantar load, which is associated with increased risk of foot ulceration.
Lower pressure values indicate better offloading.
|
Baseline (Week 0), Mid-intervention (Week 4), Post-intervention (Week 8)
|
Secundaire uitkomstmaten
Uitkomstmaat |
Maatregel Beschrijving |
Tijdsspanne |
|---|---|---|
|
Foot Health Status Questionnaire (FSHQ) Score
Tijdsspanne: Baseline (Week 0), Week 4, Week 8
|
The Foot Health Status Questionnaire (FSHQ) is a validated instrument assessing foot-related quality of life.
It includes domains of foot pain, foot function, footwear, and general foot health.
Each item is scored on a Likert scale.
Minimum score is zero and maximum score is 100.
scores are generally classified into ranges such as Very Low: 0-24.9
Low:25-49.9
Medium: 50-74.9
High: 75-100 HIgher score indicates better foot health and lower score indicates worst foot health.
|
Baseline (Week 0), Week 4, Week 8
|
Medewerkers en onderzoekers
Hier vindt u mensen en organisaties die betrokken zijn bij dit onderzoek.
Sponsor
Studie record data
Deze datums volgen de voortgang van het onderzoeksdossier en de samenvatting van de ingediende resultaten bij ClinicalTrials.gov. Studieverslagen en gerapporteerde resultaten worden beoordeeld door de National Library of Medicine (NLM) om er zeker van te zijn dat ze voldoen aan specifieke kwaliteitscontrolenormen voordat ze op de openbare website worden geplaatst.
Bestudeer belangrijke data
Studie start (Werkelijk)
1 januari 2026
Primaire voltooiing (Geschat)
30 juni 2026
Studie voltooiing (Geschat)
15 juli 2026
Studieregistratiedata
Eerst ingediend
6 juni 2026
Eerst ingediend dat voldeed aan de QC-criteria
6 juni 2026
Eerst geplaatst (Werkelijk)
11 juni 2026
Updates van studierecords
Laatste update geplaatst (Werkelijk)
17 juni 2026
Laatste update ingediend die voldeed aan QC-criteria
14 juni 2026
Laatst geverifieerd
1 juni 2026
Meer informatie
Termen gerelateerd aan deze studie
Aanvullende relevante MeSH-voorwaarden
- Endocriene systeemziekten
- Ziekten van het zenuwstelsel
- Vaatziekten
- Hart-en vaatziekten
- Neuromusculaire aandoeningen
- Ziekten van het perifere zenuwstelsel
- Suikerziekte
- Diabetische angiopathieën
- Diabetes complicaties
- Huidziektes
- Huidzweer
- Beenzweer
- Voetzweer
- Huid- en bindweefselaandoeningen
- Diabetische neuropathieën
- Diabetische voet
Andere studie-ID-nummers
- TUF/EIRB/ 195 /26
Plan Individuele Deelnemersgegevens (IPD)
Bent u van plan om gegevens van individuele deelnemers (IPD) te delen?
NEE
Informatie over medicijnen en apparaten, studiedocumenten
Bestudeert een door de Amerikaanse FDA gereguleerd geneesmiddel
Nee
Bestudeert een door de Amerikaanse FDA gereguleerd apparaatproduct
Nee
Deze informatie is zonder wijzigingen rechtstreeks van de website clinicaltrials.gov gehaald. Als u verzoeken heeft om uw onderzoeksgegevens te wijzigen, te verwijderen of bij te werken, neem dan contact op met register@clinicaltrials.gov. Zodra er een wijziging wordt doorgevoerd op clinicaltrials.gov, wordt deze ook automatisch bijgewerkt op onze website .